Month: December 2020
ObsEva Announces Additional Phase 3 PRIMROSE 1 and 2 Study Results Confirming Sustained Efficacy and Continued Safety of linzagolix in the Treatment of Uterine Fibroids
PRIMROSE 1 52-week results confirm the sustained efficacy and continued safety of linzagolix (Yselty®), with a potential best-in-class high-dose option…
Additional Phase 3 PRIMROSE 1 and 2 Study Results Confirming Sustained Efficacy and Continued Safety of linzagolix in the Treatment of Uterine Fibroids
The use of nolasiban, a novel oxytocin receptor antagonist, prior to embryo transfer: does it help?
Ernest Loumaye, MD, PhD
19th World Congress of Gynecological Endocrinology (On Line Congress 2-5 December 2020, available until 15 April 2021)
Abstract on p. 39 – part of SYMP19: Recent development in IVF
Gynecological and Reproductive Endocrinology and Metabolism 2020; Supplement 1 – Book of abstracts
ObsEva SA to present at The International Society of Gynecological Endocrinology 19th World Congress – virtual edition, December 2-5, 2020
ObsEva SA to present at The International Society of Gynecological Endocrinology 19th World Congress – virtual edition, December 2-5, 2020
Geneva, Switzerland and Boston, MA – December 1, 2020 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical…